Why Is HUTCHMED CHINA LTD ADR (HCM) Stock Moving Today?

HCM stock is up 17.19% as of 9:30 AM EDT, trading at $14.11. The sharp rise follows the announcement of a licensing and co-development agreement with GlaxoSmithKline for HMPL-A830, a preclinical oncology asset. The deal has triggered a broad market response and reinforced investor confidence in the company’s strategic positioning in the cancer therapy space.

What Happened

HUTCHMED China Ltd ADR (NASDAQ:HCM) announced a commercialization agreement with GSK for ex-China rights to HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate. The terms of the deal were not fully disclosed but are reported to be worth up to $1.3 billion. The partnership represents a significant milestone for HCM, expanding the potential reach of its oncology pipeline. The news was followed by a rating upgrade from Daiwa, which raised its stance on HCM to Buy from Hold. This upgrade added momentum to the stock’s move, which had already risen 13.7% earlier in the session.

What The Data Shows

The stock has moved up 15.9% over the past eight sessions, rising from $12.18 to $14.12. On September 3, 2026, it printed 12 fresh 52-week highs and three 52-week lows, reflecting mixed retail activity. HCM is currently trading within its 52-week range of $9.77 to $18.30. The stock’s beta of 0.44 indicates it is less volatile than the broader market. Despite a high P/E ratio of 596.3 and a year-to-date revenue decline of 8.8%, the recent partnership and analyst upgrade have driven a sharp reversal in sentiment.

What To Watch

The stock’s next key catalyst will be the release of its next earnings report, though no specific date is provided. Investors should also monitor the breadth of coverage and whether additional analysts follow Daiwa’s lead with upgrades.